Recombinant Human Granulocyte Stimulating Factor Injection can effectively regulate the hematopoiesis of granulocyte lineage in bone marrow and promote the proliferation and differentiation of hematopoietic stem cells. The active ingredient of Recombinant Human Granulocyte Stimulating Factor Injection is Recombinant Human Granulocyte Stimulating Factor, a kind of granulocyte colony-stimulating factor whose structure is originated from human, which acts on the granulocyte progenitors in bone marrow and promotes their differentiation and proliferation to neutrophils, and can improve the neutropenia induced by chemotherapy for tumors and shorten the cycle of neutropenia. In the clinic is mainly used for the treatment of neutropenia, cancer patients applying myelosuppressive chemotherapy drug injection of this drug can help prevent the occurrence of neutropenia, reduce the degree of neutropenia, accelerate the recovery of granulocytes, and reduce the risk of co-infection. It should be noted that recombinant human granulocyte stimulating factor injection may have some adverse reactions, such as muscle pain, back pain, but also can be manifested as abnormal aminotransferases, fever, headache, rash and other symptoms. Recombinant Human Granulocyte Stimulating Factor Injection is contraindicated if there is severe liver and kidney function, cardiopulmonary dysfunction. This product is usually used in hospitals by healthcare professionals.